Capital International Sarl Vir Biotechnology, Inc. Transaction History

Capital International Sarl

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$19.08 - $26.7 $333,327 - $466,449	-17,470 Reduced 61.32%	11,022 $281,000
Q1 2022 May 16, 2022	BUY	$21.19 - $40.01 $109,192 - $206,171	5,153 Added 22.08%	28,492 $733,000
Q4 2021 Feb 14, 2022	BUY	$30.97 - $54.03 $722,808 - $1.26 Million	23,339 New	23,339 $977,000
Q3 2021 Nov 15, 2021	SELL	$34.9 - $54.54 $171,010 - $267,246	-4,900 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$38.75 - $51.0 $9,300 - $12,240	240 Added 5.15%	4,900 $232,000
Q1 2021 May 14, 2021	SELL	$26.34 - $83.07 $78,888 - $248,794	-2,995 Reduced 39.12%	4,660 $239,000
Q4 2020 Feb 16, 2021	BUY	$25.51 - $43.38 $9,132 - $15,530	358 Added 4.91%	7,655 $205,000
Q3 2020 Nov 16, 2020	BUY	$28.28 - $53.6 $206,359 - $391,119	7,297 New	7,297 $251,000

228

88.4M

571K

216K

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.28B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

Stay updated on Capital International Sarl with notifications on news.